# InnoCare Pharma - Clinical Pipelines & Precision Oncology Knowledge Base

> 🌐 **Language**: English | 中文版本: [诺诚健华管线知识库](https://www.innocarepharma.com/api/llms/pipeline.txt)
>
> Comprehensive data on InnoCare's clinical pipeline, targeted mechanisms, indications, and clinical trial status.

### Orelabrutinib
- **Target**: BTK
- **Indication**: r/r CLL/SLL
- **Progress**: Market
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: r/r MCL
- **Progress**: Market
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: r/r MCL
- **Progress**: Market(Australia)
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: r/r MCL
- **Progress**: Market(Singapore)
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: r/r MZL
- **Progress**: Market
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: r/r MZL
- **Progress**: Market(Singapore)
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: 1L: CLL/SLL
- **Progress**: Market
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: 1L: MCL
- **Progress**: Registrational Trial
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Tafasitamab
- **Target**: CD19
- **Indication**: r/r DLBCL
- **Progress**: Market
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BCL2
- **Indication**: AML
- **Progress**: Head-to-head PH III
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BCL2
- **Indication**: 1L CLL/SLL
- **Progress**: Registrational Trial
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BCL2
- **Indication**: BTKi Failure r/r MCL
- **Progress**: Registrational Trial
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BLC2
- **Indication**: r/rMCL
- **Progress**: Registrational Trial
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BCL2
- **Indication**: r/r MZL
- **Progress**: Registrational Trial
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BCL2
- **Indication**: 1LAML
- **Progress**: PH I/II
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Mesutoclax
- **Target**: BCL2
- **Indication**: MDS
- **Progress**: PH I/II
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### ICP-B02
- **Target**: CD3xCD20
- **Indication**: CD20+B-cell Malignancies
- **Progress**: PH I
- **Area/Region**: Hemato-oncology
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: ITP
- **Progress**: NDA Accepted
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: MS
- **Progress**: Registrational Trial (Global)
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Orelabrutinib
- **Target**: BTK
- **Indication**: SLE
- **Progress**: Registrational Trial
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Soficitinib
- **Target**: TYK2-JH1
- **Indication**: AD
- **Progress**: Registrational Trial
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Soficitinib
- **Target**: TYK2-JH1
- **Indication**: Vitiligo
- **Progress**: PH II/III
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Soficitinib
- **Target**: TYK2-JH1
- **Indication**: PN
- **Progress**: Phase II (Global)
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Soficitinib
- **Target**: TYK2-JH1
- **Indication**: CSU
- **Progress**: PH II/III
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Soficitinib
- **Target**: TYK2-JH1
- **Indication**: Psoriasis
- **Progress**: PH II
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Fadeucravacitinib
- **Target**: TYK2-JH2
- **Indication**: Psoriasis
- **Progress**: Registrational Trial
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Fadeucravacitinib
- **Target**: TYK2-JH2
- **Indication**: CLE
- **Progress**: PH II
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### Fadeucravacitinib
- **Target**: TYK2-JH2
- **Indication**: Sjögren's Syndrome
- **Progress**: PH II
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### ICP-538
- **Target**: VAV1
- **Indication**: Autoimmune Diseases
- **Progress**: PH I
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)

### ICP-054
- **Target**: IL-17AA/AF
- **Indication**: Autoimmune Diseases
- **Progress**: PH I
- **Area/Region**: Autoimmune Diseases
- [Official Pipeline Link](https://www.innocarepharma.com/en/development/pipeline)